Viral Vector Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)

Viral Vector Vaccines Market is Segmented By Vector Type (Adeno-associated virus, Retrovirus, Lentivirus, Adenovirus, Sendai virus), By Route of Administration (Intramuscular, Subcutaneous), By Application (Gene Therapy, Vaccinology Development), By Distribution Channel(Hospitals, Vaccination center, Specialized clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Viral Vector Vaccines Market size is projected to reach USD billion by 2029, with growth at a CAGR of 14% during the forecast period (2024-2031). 

Viral vector vaccines use live viruses to carry DNA into human cells. The DNA contained in the virus encodes antigens that, once expressed in the infected human cells, elicit an immune response.

Viral Vector Vaccines Market Scope

To Get a Free Sample Sample Brochure

Viral Vector Vaccines Market Growth Dynamics

The global viral vector vaccines market growth is driven by the rising prevalence of genetic disorders, cancer, and infectious diseases, the increasing number of clinical studies using viral vectors, and the availability of funding for gene therapy development, and potential applications in novel drug delivery approaches.

Increasing investments of companies and the rising prevalence of genetic disorders, cancer, and infectious diseases are expected to drive the growth in the forecast period

There is also an increase in several genetic disorders and infectious diseases. For instance, according to the UNAIDS Statistics, in 2019, 38.0 million people worldwide were living with HIV, and 1.7 million people became newly infected with HIV. According to the same source, 26 million people accessed antiretroviral therapy at the end of June 2020. In addition, recombinant viral vectors are highly efficient carriers of sequences encoding virus-disabling sequences. Appropriate viral vectors usually need to be selected and adapted for application to treat specific viral infections. There have been significant public and private sector initiatives to develop viral vector vaccines. Many companies are investing in capacity expansion for manufacturing activities. For example, in November 2020, the contract manufacturer Vibalogics announced plans to invest USD 150 million to build a 110,000 square-foot facility near Boston in the United States. The facility will produce clinical and commercial-stage oncolytic viruses and viral vectors.

Few disadvantages of viral vector vaccines are likely to hinder the market growth

Risk of integrating into the host genome and leading to other diseases. The presence of pre-existing immunity against the vector caused by previous exposure to the virus and the production of neutralizing antibodies can reduce vaccine efficacy

COVID-19 Impact Analysis

The COVID-19 pandemic has underlined the importance of vaccine development for the global population. According to the World Health Organisation (WHO), around 151 vaccine candidates have been subjected to preclinical studies, and 42 vaccines have reached clinical trials. The importance of viral vector manufacturing is highlighted by the fact that at least two adenovirus-based vaccine candidates are currently in phase III development while another one has been approved in Russia.

Due to the relative ease of manufacturing viral vector vaccines, effective packaging cell line systems have been developed for many viral vector systems such as Ad (adenoviruses), AAV (Adeno-associated viruses), flaviviruses, and lentiviruses. This has also facilitated the rapid and efficient large-scale production of vaccine candidates eligible for clinical applications against COVID-19. In July 2020, an article was published in the ‘Nature’ journal where the chimpanzee Ad vector ChAdOx1 nCoV-19 was engineered to express the SARS-CoV-2 S protein. When this protein was subjected to immunization of mice and rhesus macaques, it induced strong humoral and cellular immune responses and prevented COVID-19 pneumonia in macaques. More such research involving viral vectors is expected to continue at least for the next one or two years. This is expected to boost the market growth.

Viral Vector Vaccines Market Segment Analysis

The adeno-associated viral vectors segment is expected to hold the largest share in this market segment

Gene therapy is an advanced medical treatment that involves the transfer of a normal or healthy gene to replace a defective gene in a cell. It can be used to cure various chronic and genetic disorders in human beings. Gene therapy is a way of fixing genetic disorders by introducing a normal and healthy gene in place of defective genes in a cell, in order to prevent or cure different types of genetic and chronic disorders for which no final cure has been developed. The market players are adopting various market strategies in developing novel products.

For instance, in April 2020, VBL Therapeutics announced that it was awarded a non-dilutive grant of up to ILS 3.175 million (approximately USD 0.9 million) by the Israel Innovation Authority to support the continued development of VBL's lead product candidate, VB-111, a first-in-class targeted anti-cancer gene-therapy agent. VB-111 is currently being evaluated in the Phase 3 potential registration study (OVAL) for the treatment of platinum-resistant ovarian cancer. In June 2019, researchers at the São Paulo State Cancer Institute (ICESP) in Brazil used a genetically manipulated virus to destroy tumor cells upon injection into mice with prostate cancer. Such developments and increasing research programs on cancer gene therapy are promoting the demand for manufacturing viral vectors.

Viral Vector Vaccines Market Geographical Analysis

The North American region holds the largest market share of the global viral vector vaccines market

U.S and Canada have more awareness and adoption rate of vaccines which has a positive impact on viral vector vaccines. U.S and Canada are where huge research & development activities are carried out. The addition of technologies, strategic improvements, and others boost the market. Many companies have been expanding their facilities and investing significant capital in the region.

For example, in April 2020, Merck KgaA and its subsidiary MilliporeSigma announced plans to spend USD 110 million to open a second viral vector facility at its Carlsbad, California facility. The projected expansion was expected to double the company’s gene therapy manufacturing capacity. In September 2019, NGen, a Canada-based non-profit that matches manufacturers with new technologies, announced that it would provide USD 1.48 million to iVexSol Canada for developing an advanced manufacturing process for lentiviral vectors.

Viral Vector Vaccines Market Competitive Landscape

The global viral vector vaccines market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Sanofi Pasteur Inc. (Sanofi S/A), AstraZeneca, CSL Ltd. (Seqirus), Abbott, GlaxoSmithKline Plc, Serum Institute of India Pvt. Ltd, Pfizer, BioNTech, F.Hoffman La Roche Ltd and Novartis. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, In January 2021, Fujifilm Corporation announced plans to invest USD 40 million, which will be used to establish a new processing facility for viral vector manufacturing and associated research.

Viral Vector Vaccines Market – Key Companies to Watch

Novartis

Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It operates business through two divisions: Innovative medicine, Sandoz. Made up of two business units – Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology – Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.

Product Portfolio: It includes product like Zolgensma, developed by AveXis for deadly spinal muscular atrophy.